Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1522-1527

  Pfeiler, G ^a   Konigsberg R ^b   Hadji, P ^c   Fitzal, F ^a   Maroske, M ^a   Dressel Ban, G ^a   Zellinger, J ^a   Exner, R ^a   Seifert, M ^a   Singer, C ^a   Gnant, M ^a   Dubsky, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Applied Cancer Research Institution for Translational Research Vienna   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; LUTEINIZING HORMONE;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OBESITY; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 84884597043     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.499     Document Type: Article

References (22)

1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3784-3796.
2. De Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 119: 145-153.
3. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511-1515.
4. Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HAT (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30: 3967-3975.
5. Ewertz M, Jensen MB, Gunnarsdóttir KÁ , Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29: 25-31.
6. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30: 2977-2980.
7. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751-757.
8. Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R (2013) The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer-an analysis of the randomized ABCSG 6a trial. Br J Cancer 109: 589-596.
9. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73: 156-166.
10. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, Kostev K (2013a) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: A retrospective datatbase analysis. Breast Cancer Res Treat 138: 185-191.
11. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2013b) The Patient's Anastrozole Compliance to Therapy (PACT) Program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24: 1505-1512.
12. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson Jr HE, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95: 1218-1226.
13. Longcope C, Baker R, Johnston CC (1986) Androgen and estrogen metabolism: Relationship to obesity. Metabolism 35: 235-237.
14. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26: 556-562.
15. Plourde PV, Dyroff M, Dukes M (1994) Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30: 103-111.
16. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29: 2653-2659.
17. Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 123: 627-635.
18. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371: 569-578.
19. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28: 3411-3415.
20. Shaw ND, Histed SN, Srouji SS, Yang J, Lee H, Hall JE (2010) Estrogen negative feedback on gonadotropin secretion: Evidence for a direct pituitary effect in women. J Clin Endocrinol Metab 95: 1955-1961.
21. van Kruijsdijk RC, van der Wall E, Visseren FL (2009) Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 18: 2569-2578.
22. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ (1996) Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73: 543-548.